Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014.

@article{Skowronski2014InterimEO,
  title={Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014.},
  author={Dm Skowronski and Catharine Chambers and Suzana Sabaiduc and Gaston De Serres and J A Dickinson and Al Winter and Kevin Fonseca and J B Gubbay and Hugues Charest and Martin Petric and Mel Krajden and S. M. Farabi Mahmud and P. Van Caeseele and T L Kwindt and Alireza Eshaghi and Nathalie Bastien and Yunhai Li},
  journal={Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin},
  year={2014},
  volume={19 5}
}
The 2013/14 influenza season to date in Canada has been characterised by predominant (90%) A(H1N1)pdm09 activity. Vaccine effectiveness (VE) was assessed in January 2014 by Canada's sentinel surveillance network using a test-negative case-control design. Interim adjusted-VE against medically-attended laboratory-confirmed influenza A(H1N1)pdm09 infection was 74% (95% CI: 58-83). Relative to vaccine, A(H1N1)pdm09 viruses were antigenically similar and genetically well conserved, with most showing… CONTINUE READING